Plus Therapeutics, Inc. (PSTV)

Market Cap	8.84M
Revenue (ttm)	6.08M
Net Income (ttm)	-11.77M
Shares Out	5.70M
EPS (ttm)	-3.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,095
Open	1.570
Previous Close	1.500
Day's Range	1.500 - 1.570
52-Week Range	0.970 - 3.210
Beta	0.57
Analysts	Strong Buy
Price Target	8.00 (+416.13%)
Earnings Date	Aug 12, 2024

About PSTV

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: PSTV

Financial Performance

In 2023, PSTV's revenue was $4.91 million, an increase of 2093.30% compared to the previous year's $224,000. Losses were -$13.32 million, -34.32% less than in 2022.

Analyst Forecast

According to one analyst, the rating for PSTV stock is "Strong Buy" and the 12-month stock price forecast is $8.0.

Price Target

$8.0

(416.13% upside)

Analyst Consensus: Strong Buy